LONDON, July 29 (Reuters) - GlaxoSmithKline (GSK.L) has pulled its application for European approval of its experimental drug mepolizumab, or Bosatria, as a treatment for a rare blood disorder called HES. It is still working to develop the medicine for asthma.
